Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
136 Results for "
SARS-CoV-2 RBD
" in MedChemExpress (MCE) Product Catalog:
Products (136)
136 Results for "SARS-CoV-2 RBD" in MCE Product Catalog:
2
1
1
1
1
1
1 Cited Publications
Cat. No.: HY-N2116
CAS No.: 111047-30-4
Cat. No.: HY-P99556
CAS No.: 2420564-02-7
Synonyms: AZD8895; CoV2-2196
Cat. No.: HY-164485
CAS No.: 2549050-07-7
Target:
Research Areas:
INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)3 and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)3, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19 .
Cat. No.: HY-P99344
CAS No.: 2423943-37-5
Synonyms: Anti-Human SARS-CoV-2; LY-3819253; LY-CoV555
Cat. No.: HY-P9802
Synonyms: SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody
Cat. No.: HY-P990814
Cat. No.: HY-P990815
Cat. No.: HY-P11464
Research Areas:
Cat. No.: HY-P10803
Cat. No.: HY-149256
CAS No.: 1282451-83-5
PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively .
Cat. No.: HY-144120
αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain
Cat. No.: HY-P991763
Cat. No.: HY-162550
CAS No.: 223611-93-6
Jobosic acid, a saturated fatty acid, is a selective SARS-CoV-2 inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant .
Cat. No.: HY-P3492
Cat. No.: HY-170767
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC50=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC50=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
